GILEAD SCIENCES, INC. Capital Expenditures
GILEAD SCIENCES, INC. (GILD) reported Capital Expenditures of $257.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $140.00M, a 30.84% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $117.00M, a 12.50% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $205.00M, a 39.46% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $147.00M, a 4.26% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $563.00M, a 7.65% increase from fiscal 2024.
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $523.00M, a 10.60% decline from fiscal 2023.
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $585.00M, a 19.64% decline from fiscal 2022.
- GILEAD SCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $728.00M, a 25.73% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $140.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $257.00M 10-Q · filed 2026-08-06 | $462.00M derived: sum of 3 quarters · filed 2026-08-06 | $609.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $117.00M 10-Q · filed 2026-05-07 | $322.00M derived: sum of 2 quarters · filed 2026-05-07 | $469.00M derived: sum of 3 quarters · filed 2026-05-07 | $576.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $205.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $352.00M derived: sum of 2 quarters · filed 2026-02-24 | $459.00M derived: sum of 3 quarters · filed 2026-08-06 | $563.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $147.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $254.00M derived: sum of 2 quarters · filed 2026-08-06 | $358.00M 10-Q · filed 2025-11-07 | $505.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $107.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $211.00M 10-Q · filed 2026-08-06 | $358.00M derived: sum of 3 quarters · filed 2026-08-06 | $499.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $104.00M 10-Q · filed 2026-05-07 | $251.00M derived: sum of 2 quarters · filed 2026-05-07 | $392.00M derived: sum of 3 quarters · filed 2026-05-07 | $522.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $147.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $288.00M derived: sum of 2 quarters · filed 2026-02-24 | $418.00M derived: sum of 3 quarters · filed 2026-02-24 | $523.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $141.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $271.00M derived: sum of 2 quarters · filed 2025-11-07 | $376.00M 10-Q · filed 2025-11-07 | $591.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $130.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $235.00M 10-Q · filed 2025-08-07 | $450.00M derived: sum of 3 quarters · filed 2026-02-24 | $572.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $105.00M 10-Q · filed 2025-05-07 | $320.00M derived: sum of 2 quarters · filed 2026-02-24 | $442.00M derived: sum of 3 quarters · filed 2026-02-24 | $581.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $215.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $337.00M derived: sum of 2 quarters · filed 2026-02-24 | $476.00M derived: sum of 3 quarters · filed 2026-02-24 | $585.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | $122.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $261.00M derived: sum of 2 quarters · filed 2024-11-12 | $370.00M 10-Q · filed 2024-11-12 | $551.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $139.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $248.00M 10-Q · filed 2024-08-08 | $429.00M derived: sum of 3 quarters · filed 2025-02-28 | $586.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $109.00M 10-Q · filed 2024-05-08 | $290.00M derived: sum of 2 quarters · filed 2025-02-28 | $447.00M derived: sum of 3 quarters · filed 2025-02-28 | $590.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $181.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $338.00M derived: sum of 2 quarters · filed 2025-02-28 | $481.00M derived: sum of 3 quarters · filed 2025-02-28 | $728.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | $157.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $300.00M derived: sum of 2 quarters · filed 2023-11-07 | $547.00M 10-Q · filed 2023-11-07 | $703.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $143.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $390.00M 10-Q · filed 2023-08-04 | $546.00M derived: sum of 3 quarters · filed 2024-02-23 | $685.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $247.00M 10-Q · filed 2023-05-03 | $403.00M derived: sum of 2 quarters · filed 2024-02-23 | $542.00M derived: sum of 3 quarters · filed 2024-02-23 | $661.00M derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $156.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $295.00M derived: sum of 2 quarters · filed 2024-02-23 | $414.00M derived: sum of 3 quarters · filed 2024-02-23 | $579.00M 10-K · filed 2024-02-23 |
| 2021-09-30 | $139.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $258.00M derived: sum of 2 quarters · filed 2022-11-02 | $423.00M 10-Q · filed 2022-11-02 | $604.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $119.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $284.00M 10-Q · filed 2022-08-08 | $465.00M derived: sum of 3 quarters · filed 2023-02-22 | $620.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $165.00M 10-Q · filed 2022-05-04 | $346.00M derived: sum of 2 quarters · filed 2023-02-22 | $501.00M derived: sum of 3 quarters · filed 2023-02-22 | $644.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $181.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $336.00M derived: sum of 2 quarters · filed 2023-02-22 | $479.00M derived: sum of 3 quarters · filed 2023-02-22 | $650.00M 10-K · filed 2023-02-22 |
| 2020-09-30 | $155.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $298.00M derived: sum of 2 quarters · filed 2021-11-03 | $469.00M 10-Q · filed 2021-11-03 | $672.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $143.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $314.00M 10-Q · filed 2021-08-05 | $517.00M derived: sum of 3 quarters · filed 2022-02-23 | $717.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $171.00M 10-Q · filed 2021-05-06 | $374.00M derived: sum of 2 quarters · filed 2022-02-23 | $574.00M derived: sum of 3 quarters · filed 2022-02-23 | $759.00M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $203.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $403.00M derived: sum of 2 quarters · filed 2022-02-23 | $588.00M derived: sum of 3 quarters · filed 2022-02-23 | $825.00M 10-K · filed 2022-02-23 |
| 2019-09-30 | $200.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $385.00M derived: sum of 2 quarters · filed 2020-11-04 | $622.00M 10-Q · filed 2020-11-04 | $870.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $185.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $422.00M 10-Q · filed 2020-08-06 | $670.00M derived: sum of 3 quarters · filed 2021-02-25 | $837.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $237.00M 10-Q · filed 2020-05-06 | $485.00M derived: sum of 2 quarters · filed 2021-02-25 | $652.00M derived: sum of 3 quarters · filed 2021-02-25 | $949.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $248.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $415.00M derived: sum of 2 quarters · filed 2021-02-25 | $712.00M derived: sum of 3 quarters · filed 2021-02-25 | $924.00M 10-K · filed 2021-02-25 |
| 2018-09-30 | $167.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $464.00M derived: sum of 2 quarters · filed 2019-11-05 | $676.00M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $297.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $509.00M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $212.00M 10-Q · filed 2019-05-08 | |||
| 2017-09-30 | $129.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $252.00M derived: sum of 2 quarters · filed 2018-11-06 | $370.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $123.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $241.00M 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $118.00M 10-Q · filed 2018-05-09 | |||
| 2016-09-30 | $198.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $402.00M derived: sum of 2 quarters · filed 2017-11-07 | $579.00M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $204.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $381.00M 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | $177.00M 10-Q · filed 2017-05-10 | |||
| 2015-06-30 | $295.00M 10-Q · filed 2015-08-05 | |||
| 2014-06-30 | $255.00M 10-Q · filed 2015-08-05 | |||
| 2013-12-31 | $134.00M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |